Dapagliflozin – do we need it registered for type 2 diabetes?

Doggrell, Sheila A. & Tuli, Rinku (2014) Dapagliflozin – do we need it registered for type 2 diabetes? Expert Opinion on Pharmacotherapy, 15(11), pp. 1631-1635.

PDF (86kB)

View at publisher



Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) promote the excretion of glucose to reduce glycated hemoglobin (HbA1c) levels. Canagliflozin was the first SGLT2 inhibitor to be approved by the US FDA for use in the treatment of type 2 diabetes, and recently dapagliflozin has also been approved.


We evaluated a recent Phase III clinical trial with dapagliflozin.


Dapagliflozin was studied as add-on therapy to sitagliptin with or without metformin, and was shown to lower HbA1c levels and body weight. The incidence of hypoglycaemia was low with dapagliflozin, but it did increase the incidence of urogenital infections. As no clear benefits have been identified for dapagliflozin over canagliflozin, which was the first gliflozin registered by the FDA, we do not fully understand why it was necessary to register dapagliflozin. Given that there are no completed cardiovascular/clinical outcome studies with dapagliflozin, and therefore no evidence of beneficial effect, it also seems premature to be using it extensively or considering it as an alternative to the clinically proven metformin.

Impact and interest:

1 citations in Scopus
Search Google Scholar™
2 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

36 since deposited on 16 Nov 2014
28 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 78692
Item Type: Journal Article
Refereed: Yes
Keywords: dapagliflozin, HbA1c, metformin, sodium glucose co-transporter 2 inhibitors, sitagliptin, type 2 diabetes, clinical outcomes
DOI: 10.1517/14656566.2014.930438
ISSN: 1744-7666
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500)
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Copyright Owner: Copyright 2014 Informa UK, Ltd.
Deposited On: 16 Nov 2014 22:24
Last Modified: 03 Sep 2015 22:40

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page